All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The phase II CARTITUDE-2 trial (NCT04133636) evaluated safety and efficacy of the B-cell maturation antigen-directed chimeric antigen receptor T-cell agent ciltacabtagene autoleucel for treatment of relapsed/refractory multiple myeloma.
During 2024 Transplantation & Cellular Therapy Meetings of the ASTCT and CIMBTR (TANDEM), Hillengass.1 presented updated results from the CARTITUDE-2 trial. We summarize the key results below.
Figure 1. Rates of overall and sustained negative MRD in cohorts A and B from CARTITUDE-2 l*
MRD, measurable residual disease.
*Adapted from Hillengass.1
†Cohort A (n = 17), cohort B (n = 15).
‡Cohort A (n = 11), cohort B (n = 13).
§Cohort A (n = 14), cohort B (n = 13).
Table 1. ORR and OS, PFS and DOR rate at 24 months*
Cohort A |
Cohort B |
|
---|---|---|
ORR, % |
95 |
100 |
OS at 24 months, % |
75.1 |
84.2 |
PFS at 24 months, % |
75 |
73.3 |
DOR at 24 months, % |
73.3 |
70.5 |
DOR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression free survival. |
Table 2. Cytokine release syndrome, ICANS, and Grade 3/4 hematologic TRAE*
%, unless otherwise stated |
Cohort A |
Cohort B |
---|---|---|
Any grade CRS |
95 |
84.2 |
Any grade ICANS |
15 |
5.3 |
Hematologic TRAE |
||
Neutropenia |
95 |
89.5 |
Lymphopenia |
80 |
47.4 |
Thrombocytopenia |
40 |
26.3 |
Anemia |
45 |
47.4 |
Leukopenia |
60 |
31.6 |
CRS, cytokine release syndrome; ICANS, immune cell associated neurotoxicity syndrome, TRAE, treatment-related adverse event. |
Key learnings |
---|
|
Subscribe to get the best content related to multiple myeloma delivered to your inbox